


Zambia

African Region



I. Epidemiological profile

Population (UN Population Division)	2023	%	Parasites and vectors
High transmission (>1 case per 1000 population)	20.7M	100	Major plasmodium species (indigenous cases): <i>P. falciparum</i> : 100 (%)*, <i>P. vivax</i> : 0 (%)
Low transmission (0-1 case per 1000 population)	-	-	Major anopheles species: <i>An. funestus</i> s.l., <i>An. gambiae</i> s.s., <i>An. arabiensis</i>
Malaria free (0 cases)	-	-	*includes mixed infections and other species of Plasmodium
Total	20.7M	-	
Reported cases and deaths			Estimates
Presumed and confirmed cases	8 470 695		Estimated cases: 3.7M [2.3M, 5.6M]
Total confirmed cases:	8 318 536		Estimated deaths: 8.5K [7.6K, 10.1K]
Confirmed cases from public sector:	4 444 197		
Confirmed cases from private sector:	2		
Confirmed cases at community level:	3 874 337		
Confirmed cases in combined health sectors:	-		
Reported deaths:	1616		

II. Intervention policies and strategies

Intervention	Policies/Strategies	Yes/No	Year adopted	Medicine	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2000	AL	2003
	ITN distributed by mass campaign	Yes	2000	AL	2003
IRS	IRS is recommended	Yes	-	NA	-
	DDT is used for IRS	No	-	AS	2017
Larval control	Use of Larval Control	Yes*	2012	NA	-
IPT	IPT used to prevent malaria during pregnancy	Yes	2000	Dosage of primaquine for radical treatment of <i>P. vivax</i> : 0.25 mg/Kg (14 days)	
Diagnosis	Malaria diagnosis using RDT is free of charge in the public sector	Yes	2003	Type of RDT used (public): Pf only	
	Malaria diagnosis using microscopy is free of charge in the public sector	Yes	2001		
	Malaria diagnosis is free in the private sector	Yes	2001		
Treatment	ACT is free for all ages in public sector	Yes	2003		
	The sale of oral artemisinin-based monotherapies (oAMTs)	banned	2017		
	Single low dose of primaquine (0.75 mg base/kg) with ACT to reduce transmissibility of <i>P. falciparum</i>	No	-		
	Primaquine is used for radical treatment of <i>P. vivax</i>	NA	-		
	G6PD test is a requirement before treatment with primaquine	NA	-		
	Directly observed treatment with primaquine is undertaken	NA	-		
	System for monitoring of adverse reaction to antimalarials exists	Yes	2006		
Surveillance	Malaria is a notifiable disease	Disc	-		
	ACD for case investigation (reactive)	Yes	2011		
	ACD at community level of febrile cases (pro-active)	No	-		
	Mass screening is undertaken	Yes	2015		
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-		
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-		
	Case investigation undertaken	No	-		
	Foci investigation undertaken	No	-		
	Case reporting from private sector is mandatory	No	-		

Yes* = Policy adopted, but not implemented in 2023

Disc = Discontinued


Earliest year that policy is adopted was adjusted based on the earliest year that the WHO policy was recommended

III.

Estimated and reported cases




Treatment seeking and reporting completeness




IV.

Cases tested and treated




Test positivity



Source: DHS 2014,2018


Source: DHS 2014,2018

V. Confirmed malaria cases per 1000 population at risk and ABER




ABER=smeas examined in a year X100 / Total population. Includes cases that are imported and introduced

Malaria inpatients and deaths




V. Coverage of ITN and IRS




Source: DHS 2014,2018

Sources of financing



VI. Government expenditure by intervention in 2023



Footnotes
(est.) : WHO estimates based on the survey

Country profiles are generated automatically based on data reported by countries. They are available for all current malaria endemic countries and territories asked to report to the Global Malaria Programme annually. Country profiles are based on data validated by the countries as of 14 November 2024.

Further information on the methods used to estimate malaria cases and an explanation for the gap between estimated and reported confirmed indigenous cases is provided [mpac-april2018-erq-report-malaria-burden-session6.pdf \(who.int\)](#)